A programmable nanoplatform for inflammatory-state reprogramming in psoriasis treatment.
7 affiliations
- 1The Affiliated Hospital of Yanbian University (Yanbian Hospital), Yanji, China.
- 2Nursing College of Yanbian University, Yanji, 133000, China.
- 3State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.
- 4Changchun University of Chinese Medicine, 1035 Bo Shuo Road, Changchun City, 130117, Jilin Province, China. [email protected].
- 5State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China. [email protected].
- 6State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China. [email protected].
- 7The Affiliated Hospital of Yanbian University (Yanbian Hospital), Yanji, China. [email protected].
Abstract
Psoriasis is a chronic, immune-mediated inflammatory skin disease. Although current treatments alleviate symptoms, they primarily focus on inflammation suppression through single-target approaches, which fail to comprehensively address the complex pathological imbalances. To overcome this limitation, we developed a programmable delivery system based on a nanocomposite material composed of Tannic acid (TA), Cerium (Ce), and Luteolin (Lut), integrated into an in situ gelling hydrogel platform (TA-Ce-Lut-Gel), enabling multi-dimensional treatment strategy for psoriasis by precisely modulating oxidative stress, immune responses, and skin microbiota. The TA-Ce-Lut metal-polyphenol nanoparticles, constructed through coordination bonds, exhibited a size of 177.30 ± 0.55 nm and high encapsulation efficiency of 72.89 ± 5.32%. Upon incorporation into the hydrogel, this system provided a localized and sustained drug depot. In an imiquimod-induced mouse model of psoriasis (both ear and back), TA-Ce-Lut-Gel significantly reduced skin inflammation, improved skin thickness, erythema, and scaling, showing superior efficacy compared to traditional anti-inflammatory treatments. This system alleviated ROS levels, regulated macrophage M2 polarization, and reshaped the immune response, while also modulating the TRAF6/NF-κB/STAT3 signaling pathway to significantly inhibit pro-inflammatory cytokine secretion. Additionally, combined with NIR irradiation, TA-Ce-Lut-Gel enhanced transdermal drug delivery and antioxidant activity, further enhancing therapeutic effects and promoting skin microbiota recovery. This study presents an effective platform for localized precise treatment of psoriasis, overcoming the limitations of traditional single-target anti-inflammatory therapies and offering a potential strategy for the treatment of other immune-mediated diseases, with broad clinical application prospects.
Related
- NIR-responsive carbon monoxide nanoplatform for synergistic antibacterial and anti-inflammatory therapy of refractory keratitis and biofilm-infected wounds
- Hematological inflammatory markers as predictors of atherosclerotic progression in patients with psoriasis: A retrospective case–control study from the SH-YIMED database
- Phenotype Switching in Pediatric Inflammatory Skin Diseases During Biologic Therapy: A Literature Review Focused on Atopic Dermatitis and Psoriasis
- Computationally Guided Design of Two Novel Phosphodiesterase-4 Inhibitors for Treatment of Plaque Psoriasis
- Obesity-Associated Inflammatory Reprogramming Impairs a Granulomatous Response to Leishmania infantum
BibTeX
@article{chen2026programmable,
title = {{A programmable nanoplatform for inflammatory-state reprogramming in psoriasis treatment.}},
author = {Zhihua Chen and Jinyu Zhao and Shiqi Huang and Ge Lou and Mingji Jin and Zheng Nan and Zhonggao Gao and Shuangqing Wang and Jingchun Jin},
journal = {Journal of nanobiotechnology},
year = {2026},
month = jul,
doi = {10.1186/s12951-026-04842-z},
url = {https://europepmc.org/article/MED/42902367},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - A programmable nanoplatform for inflammatory-state reprogramming in psoriasis treatment.
AU - Zhihua Chen
AU - Jinyu Zhao
AU - Shiqi Huang
AU - Ge Lou
AU - Mingji Jin
AU - Zheng Nan
AU - Zhonggao Gao
AU - Shuangqing Wang
AU - Jingchun Jin
PY - 2026
DA - 2026/07/01
JO - Journal of nanobiotechnology
DO - 10.1186/s12951-026-04842-z
UR - https://europepmc.org/article/MED/42902367
AB - Psoriasis is a chronic, immune-mediated inflammatory skin disease. Although current treatments alleviate symptoms, they primarily focus on inflammation suppression through single-target approaches, which fail to comprehensively address the complex pathological imbalances. To overcome this limitation, we developed a programmable delivery system based on a nanocomposite material composed of Tannic acid (TA), Cerium (Ce), and Luteolin (Lut), integrated into an in situ gelling hydrogel platform (TA-Ce-Lut-Gel), enabling multi-dimensional treatment strategy for psoriasis by precisely modulating oxidative stress, immune responses, and skin microbiota. The TA-Ce-Lut metal-polyphenol nanoparticles, constructed through coordination bonds, exhibited a size of 177.30 ± 0.55 nm and high encapsulation efficiency of 72.89 ± 5.32%. Upon incorporation into the hydrogel, this system provided a localized and sustained drug depot. In an imiquimod-induced mouse model of psoriasis (both ear and back), TA-Ce-Lut-Gel significantly reduced skin inflammation, improved skin thickness, erythema, and scaling, showing superior efficacy compared to traditional anti-inflammatory treatments. This system alleviated ROS levels, regulated macrophage M2 polarization, and reshaped the immune response, while also modulating the TRAF6/NF-κB/STAT3 signaling pathway to significantly inhibit pro-inflammatory cytokine secretion. Additionally, combined with NIR irradiation, TA-Ce-Lut-Gel enhanced transdermal drug delivery and antioxidant activity, further enhancing therapeutic effects and promoting skin microbiota recovery. This study presents an effective platform for localized precise treatment of psoriasis, overcoming the limitations of traditional single-target anti-inflammatory therapies and offering a potential strategy for the treatment of other immune-mediated diseases, with broad clinical application prospects.
SN - 1477-3155
ER -